| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919105 | Radiotherapy and Oncology | 2013 | 6 Pages |
Abstract
ISHT is well-tolerated and does not affect treatment-related early or late complications. Improvements in DFS and LC were not observed following the addition of ISHT to ISBT.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Agnieszka Zolciak-Siwinska, Norbert Piotrkowicz, Joanna Jonska-Gmyrek, Maria Nicke-Psikuta, Wojciech Michalski, Maryla KawczyÅska, MichaÅ Bijok, Krzysztof Bujko,